https://www.zacks.com/stock/news/2258769/cvs-health-cvs-ascends-while-market-falls-some-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2258769
Apr 19, 2024 - In the most recent trading session, CVS Health (CVS) closed at $69.75, indicating a +0.52% shift from the previous trading day.
zc:5144718068181477948
0
https://www.zacks.com/stock/news/2258053/cvs-health-cvs-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2258053
Apr 18, 2024 - CVS Health (CVS) closed at $69.39 in the latest trading session, marking a +1.15% move from the prior day.
zc:4908704362970467552
0
https://seekingalpha.com/news/4090466-cvs-favors-humira-copycats-hurting-abbvies-market?source=feed_sector_healthcare
Apr 17, 2024 - CVS Health's (CVS)decision to drop coverage for Humira and favor its cheaper biosimilars is hurting AbbVie's (ABBV) market dominance. Read more here.
0
sa:-8897702083989246504
0
https://www.zacks.com/stock/news/2254862/cvs-health-cvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2254862
Apr 12, 2024 - In the closing of the recent trading day, CVS Health (CVS) stood at $68.64, denoting a -1.58% change from the preceding trading day.
zc:-36701119599330246
0
https://www.zacks.com/stock/news/2252981/cvs-health-cvs-stock-drops-despite-market-gains-important-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2252981
Apr 09, 2024 - CVS Health (CVS) closed at $73.36 in the latest trading session, marking a -1.45% move from the prior day.
zc:-2593712065220776016
0
https://www.zacks.com/stock/news/2252013/fastenal-fast-to-post-q1-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2252013
Apr 08, 2024 - Fastenal's (FAST) Q1 results are likely to reflect manufacturing growth, albeit at a slow pace, with a strong digital strategy and a balanced onsite/offsite mix. Yet, slowing industrial markets are a concern.
zc:-9078637482007820009
0
https://www.zacks.com/stock/news/2251113/cvs-health-cvs-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2251113
Apr 05, 2024 - Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
zc:-5742619434248550377
0
https://www.cnbc.com/2024/04/04/cvs-drug-plans-will-cover-otc-birth-control-pill-opill.html
Apr 04, 2024 - The decision by CVS could open the door for more people to prevent unintended pregnancies without a prescription.
0
cnbc:-4780074801026370554
0
https://seekingalpha.com/news/4087383-cvs-health-to-cover-perrigo-otc-birth-control-pill?source=feed_sector_healthcare
Apr 04, 2024 - CVS Health (CVS) plans to have its drug plans cover over-the-counter birth control products, including Perrigo (PRGO) Opill. Read more here.
0
sa:-5723613352885285034
0
https://www.zacks.com/stock/news/2250087/cvs-health-cvs-outperforms-broader-market-what-you-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2250087
Apr 03, 2024 - CVS Health (CVS) closed the most recent trading day at $74.60, moving +1.06% from the previous trading session.
zc:-8476937402307991110
0